Skip to content
Open access

NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORES AS PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT STUDY AT KING HUSSEIN MEDICAL CENTER

Sep 2026 · World Journal of Advanced Research and Reviews · 0 citations

Abstract

Background: Inflammatory Bowel Disease (IBD) is associated with various hepatic manifestations, with non-alcoholic fatty liver disease (NAFLD) being the most common. Non-invasive fibrosis scores (FIB-4, NFS) are validated tools for risk-stratifying NAFLD patients. Whether these scores predict IBD clinical progression remains unknown. Aims: This study aimed to evaluate whether baseline non-invasive liver fibrosis scores (FIB-4 and NFS) can predict clinical disease progression in an IBD cohort. Methods: A retrospective longitudinal cohort study included 266 adult patients with confirmed Crohn's disease or Ulcerative colitis followed at King Hussein Medical Center for a minimum of 2 years (January 2022 – January 2024). Baseline FIB-4 and NFS were calculated and patients categorized into low-risk versus intermediate/high-risk fibrosis groups. Primary outcome was a composite of IBD progression: IBD-related hospitalization, systemic corticosteroid requirement, escalation to biologic therapy, or new intestinal complication. Time-to-event analysis used Kaplan-Meier and Cox proportional hazards models adjusting for traditional IBD risk factors. Results: Among 266 patients (mean age 42.3 ± 14.8 years, 54.1% male), 62.4% had Ulcerative colitis and 37.6% Crohn's disease. Elevated fibrosis risk (intermediate/high FIB-4) was present in 28.2%. Over 2-year follow-up, 102 patients (38.3%) experienced IBD progression. Patients with elevated fibrosis risk had significantly higher progression rates (58.7% vs. 30.4%, p<0.001). On multivariate Cox regression, elevated FIB-4 (HR=2.45, 95% CI: 1.62–3.71) and elevated NFS (HR=2.18, 95% CI: 1.45–3.28) were independent predictors of IBD progression after adjusting for age, sex, disease duration, and baseline therapy. Conclusion: Non-invasive liver fibrosis scores, particularly FIB-4, are independent predictors of disease progression in IBD patients. These easily calculated scores may serve as valuable prognostic tools for risk stratification in routine IBD management.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.